Lijun Sun

机构：Guangdong Medical College, Capital Medical University, Beijing YouAn Hospital, Beijing Center for Disease Prevention and Control · ORCID：0000-0002-5954-6679

发表论文 59 篇 · 总被引 1715 次 · h-index 19

代表论文

• Factors associated with human immunodeficiency virus‐1 low‐level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China (2022 · HIV Medicine · 被引 24)
• (5R)-5-hydroxytriptolide for HIV immunological non-responders receiving ART: a randomized, double-blinded, placebo-controlled phase II study (2023 · The Lancet Regional Health - Western Pacific · 被引 23)
• Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96 (2023 · The Lancet Regional Health - Western Pacific · 被引 21)
• Rapid Initiation of Antiretroviral Therapy With Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Versus Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate in HIV–Positive Men Who Have Sex With Men in China: Week 48 Results of the Multicenter, Randomized Clinical Trial (2024 · Clinical Infectious Diseases · 被引 19)
• Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study (2022 · Journal of Infection · 被引 17)
• An open-label evaluation of safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide for post-exposure prophylaxis following potential exposure to human immunodeficiency virus-1 (2022 · Chinese Medical Journal · 被引 12)